RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression

NCT05940896 | Recruiting Phase 1

• 1 other identifier: RC48-C019
• Study Type: interventional
• Target: 24
• Locations: 1 country
• Sites: 1

Brief Summary

To evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of Disitamab Vedotin(DV, RC48-ADC) intravenously combined with radiotherapy in the treatment of locally advanced solid tumors with HER2 expression

Conditions

Solid Tumor

Keywords

HER2 expression; solid tumor

Outcome Measures

Primary Outcomes (2)

• DLT

  Dose limiting toxicity (DLT)

  First DV dose to 28 days after the last RT

• AE

  the incidence and severity of adverse events (AE);

  First DV dose to 90 days after the last RT

Secondary Outcomes (3)

• PK Characterize

  Cycle1Day1 to Cycle1Day8 (each cycle is 14 days)

• Immunogenicity assessment

  Cycle1Day1 to Cycle1Day8 (each cycle is 14 days)

• ORR

  approximately 2 years from the first dose

Study Arms (1)

Dose escalation

EXPERIMENTAL

DV is given intravenously once every 2 weeks, (dose escalation plan: 1.0mg/kg, 1.5mg/kg, 2.0mg/kg, 2.5mg/kg). DV will be administered at least 2 times during the treatment, and the final DV dose needs to be completed before the last radiotherapy.

Drug: Disitamab vedotin

Interventions

Disitamab vedotin DRUG

Disitamab Vedotin intravenously combined with radiotherapy (concurrent)

Also known as: RC48-ADC

Dose escalation

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Voluntary signed informed consent,
• Male or female, aged ≥18 years,
• Predicted survival ≥ 12 weeks;
• Based on the investigator's evaluation (histopathological classification and clinical staging), patients with locally advanced solid tumors (head and neck squamous cell carcinoma, esophageal carcinoma, urothelium carcinoma, cervical carcinoma, etc), whose SOC is concurrent chemoradiation and cannot be surgically removed, are ineligible or refuse the standard chemotherapy.
• The subject has not been given any anti-tumor systemic therapy or radiotherapy for locally advanced solid tumors in the past
• HER2 expression is confirmed by the site: IHC 1+, 2+or 3+;
• At least one measurable lesion according to RECIST 1.1.
• ECOG performance status score of 0 or 1;
• Adequate heart, bone marrow, liver, and kidney functions, which should meet the following standards within 7 days before the study drug is given (based on the normal values of the site) :
• Left ventricular ejection fraction ≥ 50%; Hemoglobin ≥ 9g/dL; Absolute neutrophil count (ANC) ≥ 1.5 × 10\^9/L； Platelets ≥ 100 × 10\^9/L； Serum total bilirubin ≤ 1.5 times the upper limit of normal value (ULN); ALT and AST ≤ 2.5 × ULN； Blood creatinine ≤ 1.5 × ULN or calculate creatinine clearance rate (CrCl) ≥ 50 mL/min according to Cockcroft Fault formula method;
• Female subjects: should be surgically sterilized, postmenopausal, or agree to use a medically approved contraceptive (such as an intrauterine device, contraceptives, or condoms) during study treatment and within 6 months after the end of study, and their blood pregnancy test must be negative within 7 days prior to study enrollment and they must be non-lactating. Male subjects: should be surgically sterile, or agree to use a medically approved contraceptive during study treatment and within 6 months after the end of study;
• Willing and able to comply with the schedules of the trial and follow-up procedures.

You may not qualify if:

• Received anti-tumor therapy before this study, including radiotherapy, target therapy, immunotherapy, and any anti-tumor clinical studies;
• The subject was given a major surgery and did not fully recover within 4 weeks prior to the study;
• Serum virology examination (based on the normal value of the site):
• HBsAg or HBcAb test results are positive, while HBV DNA copy is detected as positive; The HCVAb test result is positive (only when the PCR test result for HCV RNA is negative, can it be selected for this study); The HIVAb test result is positive.
• The subject was given live vaccine within 4 weeks before the study drug is given or planed to receive any vaccine during the study period (except for Covid-19 vaccine);
• Heart failure≥ 3 grade（NYHA）
• Serious arteriovenous thrombotic events or cardiovascular and cerebrovascular accidents, such as deep vein thrombosis, pulmonary embolism, cerebral infarction, cerebral hemorrhage, myocardial infarction, etc., occurred within one year before the study drug is given, except for lacunar cerebral infarction without symptoms or clinical intervention;
• There are active or progressive infections that require systematic treatment, such as active pulmonary tuberculosis;
• There are systemic diseases that have not been controlled stably as judged by the investigator, including diabetes, hypertension, cirrhosis, interstitial pneumonia, obstructive pulmonary disease, etc;
• Active autoimmune diseases that require systematic treatment (such as the use of immunomodulators, corticosteroids, or immunosuppressants) prior to the start of drug administration, allowing for related alternative treatments (such as thyroid hormone, insulin, or physiological corticosteroid replacement therapy for renal or pituitary dysfunction);
• Patients with other malignant tumors within 5 years prior to the start of study administration;
• Previously received other antibody conjugated drug treatments;
• Those who are known to be allergic to recombinant humanized anti HER2-ADC and components;
• Pregnant or lactating women;

Sponsors & Collaborators

• RemeGen Co., Ltd.: lead

Study Sites (1)

Shandong Cancer hospital &Institute

Jinan, Shandong, China

RECRUITING

MeSH Terms

Interventions

disitamab vedotin

Study Officials

• Jinming Yu, MD

  Shandong Cancer Hospital and Institute

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Jianmin Fang, PhD

CONTACT

86-010-58075561; jianminfang@hotmail.com

Na Su, PhD

CONTACT

86-010-65391479; na.su@remegen.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: DV is given intravenously once every 2 weeks, (dose escalation plan: 1.0mg/kg, 1.5mg/kg, 2.0mg/kg, 2.5mg/kg). DV will be administered at least 2 times during the treatment, and the final DV dose needs to be completed before the last radiotherapy. Concurrent standard radiotherapy for solid tumors is given for 5-7 weeks, 5 times per week.

Study Record Dates

• First Submitted: May 8, 2023
• First Posted: July 11, 2023
• Study Start: June 29, 2023
• Primary Completion: November 16, 2024
• Study Completion (Estimated): February 28, 2027
• Last Updated: November 27, 2023

Record last verified: 2023-11

Locations

CN (1)